Cargando…

Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment

Rheumatoid arthritis (RA) patients are at high risk of cardiovascular (CV) events, and the chronic inflammatory state may generate quantitative and qualitative changes in lipoprotein fractions. The anti-IL-6 receptor tocilizumab (TCZ), even if effective in inflammation and joint damage prevention, d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cacciapaglia, Fabio, Anelli, Maria Grazia, Rinaldi, Angela, Fornaro, Marco, Lopalco, Giuseppe, Scioscia, Crescenzio, Lapadula, Giovanni, Iannone, Florenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204176/ https://www.ncbi.nlm.nih.gov/pubmed/30405318 http://dx.doi.org/10.1155/2018/2453265

Ejemplares similares

Effective tumour necrosis factor-blocking therapy reduces reactive oxygen metabolite level in rheumatoid arthritis
por: Cacciapaglia, Fabio, et al.
Publicado: (2016)

Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-Analysis
por: Cacciapaglia, Fabio, et al.
Publicado: (2022)

Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors
por: Venerito, Vincenzo, et al.
Publicado: (2022)

Interleukin-1 as a Common Denominator from Autoinflammatory to Autoimmune Disorders: Premises, Perils, and Perspectives
por: Lopalco, Giuseppe, et al.
Publicado: (2015)

Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors
por: Barone, Michele, et al.
Publicado: (2018)

From Bench to Bedside in Rheumatoid Arthritis from the “2022 GISEA International Symposium”
por: Vitale, Antonio, et al.
Publicado: (2023)

Body mass index and adipokines/cytokines dysregulation in systemic sclerosis
por: Iannone, Florenzo, et al.
Publicado: (2021)

Radiomics to predict the mortality of patients with rheumatoid arthritis-associated interstitial lung disease: A proof-of-concept study
por: Venerito, Vincenzo, et al.
Publicado: (2023)

Chemerin/ChemR23 pathway: a system beyond chemokines
por: Iannone, Florenzo, et al.
Publicado: (2011)

Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study
por: Venerito, Vincenzo, et al.
Publicado: (2023)

Anti-atherogenic Modification of Serum Lipoprotein Function in Patients with Rheumatoid Arthritis after Tocilizumab Treatment, a Pilot Study
por: Greco, Daniela, et al.
Publicado: (2020)

Atherogenic lipid profiles and its management in patients with rheumatoid arthritis
por: Nurmohamed, Michael T
Publicado: (2007)

Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behcet's Disease
por: Lopalco, Giuseppe, et al.
Publicado: (2015)

Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives
por: Rotondo, Cinzia, et al.
Publicado: (2015)

Review of tocilizumab in the treatment of rheumatoid arthritis
por: Okuda, Yasuaki
Publicado: (2008)

Tocilizumab in the treatment of rheumatoid arthritis and beyond
por: Shetty, Anjali, et al.
Publicado: (2014)

Tocilizumab: A Review in Rheumatoid Arthritis
por: Scott, Lesley J.
Publicado: (2017)

Cytokine Signatures in Mucocutaneous and Ocular Behçet’s Disease
por: Lopalco, Giuseppe, et al.
Publicado: (2017)

COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence
por: Venerito, Vincenzo, et al.
Publicado: (2020)

A Machine Learning Approach to Predict Remission in Patients With Psoriatic Arthritis on Treatment With Secukinumab
por: Venerito, Vincenzo, et al.
Publicado: (2022)

Safety and Efficacy of Tocilizumab for the Treatment of Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2012)

Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
por: Pers, Yves-Marie, et al.
Publicado: (2011)

Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence
por: Iannone, Florenzo, et al.
Publicado: (2022)

Proinflammatory Cytokines and Antiskin Autoantibodies in Patients With Inherited Epidermolysis Bullosa
por: Annicchiarico, Giuseppina, et al.
Publicado: (2015)

Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions
por: Mahamid, Mahmud, et al.
Publicado: (2011)

Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab
por: Yilmaz, Sedat, et al.
Publicado: (2013)

Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab
por: Rubbert-Roth, Andrea, et al.
Publicado: (2016)

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab
por: Negoescu, Andra F., et al.
Publicado: (2014)

Tocilizumab-Induced Dermatosis in a Patient With Rheumatoid Arthritis
por: Babkoor, Doaa, et al.
Publicado: (2022)

Update on the Medical Management of Gastrointestinal Behçet's Disease
por: Lopalco, Giuseppe, et al.
Publicado: (2017)

Rheumatoid Arthritis from Easy to Complex Disease: From the “2022 GISEA International Symposium”
por: Perniola, Simone, et al.
Publicado: (2023)

Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis
por: Hushaw, Linda L, et al.
Publicado: (2010)

Tocilizumab: A Review of Its Safety and Efficacy in Rheumatoid Arthritis
por: Jones, Graeme, et al.
Publicado: (2010)

Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review
por: Al-Shakarchi, Israa, et al.
Publicado: (2013)

Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis
por: Baek, Han Joo, et al.
Publicado: (2019)

Progressive Multifocal Leukoencephalopathy during Tocilizumab Treatment for Rheumatoid Arthritis
por: Anada, Mamiko, et al.
Publicado: (2020)

Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis
por: Gualtierotti, Roberta, et al.
Publicado: (2019)

Organizing Pneumonia Induced by Tocilizumab in a Patient with Rheumatoid Arthritis
por: Gouveia, Pedro A, et al.
Publicado: (2020)

Metabolic Syndrome and Atherogenic Indices in Rheumatoid Arthritis and their Relationship with Disease Activity: A Hospital-based Study from Northeast India
por: Bhattacharya, Prasanta Kumar, et al.
Publicado: (2020)

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries
por: Lauper, Kim, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jtmljemn2msdku75kj9b5tht2d